<DOC>
	<DOCNO>NCT02770365</DOCNO>
	<brief_summary>To compare safety efficacy Perrigo 's drug product compare FDA approve drug product treatment vulvar vaginal atrophy .</brief_summary>
	<brief_title>Comparative Safety Efficacy Two Treatments Treatment Vulvar Vaginal Atrophy</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>postmenopausal female otherwise healthy , 30 75 year age . ≤ 5 % superficial cell vaginal smear cytology Visit 1/Screening . vaginal pH &gt; 5.0 Visit 1/Screening Have least one selfassessed moderate severe symptom Vulvar Vaginal Atrophy identify subject bothersome For woman intact uterus , vaginal ultrasonography confirmation Visit 1/Screening inactive endometrial line endometrial thickness le 4 mm . Systolic blood pressure great 150 mm Hg diastolic blood pressure great 90 mm Hg Visit 1/Screening Visit 2/Randomization Undiagnosed vaginal bleeding history significant risk factor endometrial cancer . Known , suspect , history cancer breast mammogram indicate abnormality subject history cervical cancer . Vaginal ultrasonography woman intact uterus confirm endometrial thickness 4mm History hypersensitivity allergy estradiol study medication ingredient . Known suspect estrogendependent neoplasia . Has deep vein thrombosis , pulmonary embolism history condition . • Subject active arterial thromboembolic disease ( e. g. stroke , myocardial infarction ) history condition . Known acute chronic hepatic disease dysfunction</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>